Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $2.20 Price Target at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target reduced by stock analysts at UBS Group from $5.00 to $2.20 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target would indicate a potential downside of 6.18% from the company’s previous close.

Several other research firms have also commented on ZNTL. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Guggenheim cut their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.69.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL opened at $2.35 on Tuesday. Zentalis Pharmaceuticals has a fifty-two week low of $2.13 and a fifty-two week high of $18.07. The firm has a market capitalization of $167.10 million, a PE ratio of -0.95 and a beta of 1.86. The stock’s fifty day moving average is $3.04 and its 200 day moving average is $3.32.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. Equities analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Verition Fund Management LLC grew its position in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Renaissance Technologies LLC raised its position in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares during the period. GSA Capital Partners LLP boosted its holdings in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after acquiring an additional 353,384 shares during the period. Primecap Management Co. CA lifted its holdings in Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after buying an additional 265,690 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Zentalis Pharmaceuticals by 126.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock worth $843,000 after buying an additional 127,868 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.